![logo](/logos/ELYM.webp)
Eliem Therapeutics, Inc.
NASDAQ:ELYM
7.39 (USD) • At close September 6, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Eliem Therapeutics, Inc. |
Symbool | ELYM |
Munteenheid | USD |
Prijs | 7.39 |
Beurswaarde | 495,574,871 |
Dividendpercentage | 0% |
52-weken bereik | 2.35 - 11.55 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Andrew Levin M.D., Ph.D. |
Website | https://www.eliemtx.com |
An error occurred while fetching data.
Over Eliem Therapeutics, Inc.
Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain, which is in Phase IIa clinical
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)